ArticleThoracic cancer2015
Percutaneous radiofrequency ablation for medically inoperable patients with clinical stage I non-small cell lung cancer.
Article in Thoracic cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Expert consensus on image-guided radiofrequency ablation of pulmonary tumors: 2018 edition.Thoracic cancer · 2018Guideline
- Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis.International journal of radiation oncology, biology, physics · 2016Pooled it
- Electrodes of radiofrequency ablation for malignant lung tumors: a narrative review of advances, applications, and prospects.Journal of thoracic disease · 2026Review
- Circulating tumor DNA as prognostic markers of non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.Translational lung cancer research · 2025Article
- Lung imaging methods: indications, strengths and limitations.Breathe (Sheffield, England) · 2024Review
- Assessment of safety margin after microwave ablation of stage I NSCLC with three-dimensional reconstruction technique using CT imaging.BMC medical imaging · 2021Article
- Radiofrequency ablationJournal of Cancer · 2021Article
- Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: An Updated Review of Literature from the Last Decade.Interventional radiology (Higashimatsuyama-shi (Japan) · 2020Review
- [Advances and Challenges of Local Thermal Ablation in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
- [Expert Consensus for Image-guided Radiofrequency Ablation of Pulmonary Tumors (2018 Version)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2018Review
- Clinical assessment of computed tomography guided radiofrequency ablation in the treatment of inoperable patients with pulmonary tumors.Journal of thoracic disease · 2017Article
- Thermal ablation for the treatment of primary and secondary pulmonary malignancies.Journal of thoracic disease · 2017Article
- Radiofrequency ablation in primary non-small cell lung cancer: What a radiologist needs to know.The Indian journal of radiology & imagingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA retrospective evaluation of percutaneous radiofrequency ablation (RFA) in medically inoperable patients with clinical stage I non-small cell lung cancer (NSCLC).
methodsBetween 2008 and 2014, 29 medically inoperable patients with clinical stage I NSCLC underwent percutaneous RFA. We evaluated the feasibility, safety, and effectiveness.
resultsThere were 18 men and 11 women with a median age of 78.0 years (range 56-85), mean 76.0 years. No procedure-related deaths occurred in any of the 33 ablation procedures. The mean follow-up was 25 months. The incidence of local tumor progression was 21.0% at 25 months of median time to progression after the initial RFA. The mean overall survival (OS) was 57 months (95% confidence interval (CI) 44-70 months). The mean cancer-specific survival CSS was 63 months (95% CI 50-75 months). OS was 90.5% ± 6.4% at one year, 76.4% ± 10.7% at two, and 65.5% ± 13.6% at three years. CSS was 95.2% ± 4.6% at one, 86.6% ± 9.3% at two, and 74.2% ± 13.9% at three years in all patients. The survival for stage IA and IB cancers were 87.5% and 92.3% at one, 87.5% and 73.4% at two, and 87.5% and 58.7% at three years, respectively. Survival rates were not significantly different between the two groups (P = 0.596), with mean survival times of 65 (95% CI: 51-79 months) and 55 months (95% CI: 38-71 months), respectively.
conclusionPercutaneous RFA is a safe, feasible, and effective procedure in medically inoperable clinical stage I NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.